Cabaletta Bio, Inc. · NASDAQ:CABA
Cabaletta Bio — Investor Presentation (November 2023)
27 slides from Cabaletta Bio's investor presentation, Nov 9, 2023
Slide 1: Corporate Presentation November 2023
Corporate Presentation NOVEMBER 2023 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection wi
Slide 3: Develop and launch the first curative targeted cellular therapies for autoimmune diseases
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases
Slide 4: Leveraging years of experience with cellular therapy in autoimmunity to initiate CABA-201 trials
Leveraging years of experience with cellular therapy in autoimmunity to initiate CABA-201 clinical trials Cabaletta®: Pursuing cures for a broad range of autoimmune diseases CARTA – Chimeric Antigen Receptor T cells for Autoimmunity; CAART – Chimeric AutoAntibody Receptor T cells; IND – Investigatio
Slide 5: One CABA platform, two strategies to address autoimmune diseases
One CABA™ platform, two strategies to address autoimmune diseases Complementary strategies to optimize clinical outcomes using cellular therapies in autoimmune diseases Mackensen, Andreas, et al. "Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus." Nature Medicine (2022): 1-9.
Slide 6: Biologic opportunity for cure or treatment in dozens of autoimmune diseases
6 Biologic opportunity for cure or treatment may be possible in dozens of autoimmune diseases* CABA™ platform may apply across a range of autoimmune diseases Illustrative list of autoimmune diseases where B cells may play a role in initiating or maintaining disease, and where biologic opportunity fo
Slide 7: CABA Platform Pipeline
CABA™ Platform Program Indication Discovery Preclinical Phase 1/2 Phase 2/3 CARTA Chimeric Antigen Receptor T cells for Autoimmunity CABA-201 4-1BB CD19-CAR T Myositis (IIM, Idiopathic Inflammatory Myopathy)1 CARTA Chimeric Antigen Receptor T cells for Autoimmunity Systemic Lupus Erythematous (SLE)1
Slide 8: Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201
Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201
Slide 9: Emerging academic clinical data with 4-1BB CD19-CAR T
Emerging academic clinical data with 4-1BB CD19-CAR T1 in… SLE – Systemic lupus erythematosus; SLEDAI-2K – Systemic Lupus Erythematosus Disease Activity Index 2000; EUSAR – European Scleroderma Trials and Research The construct utilized in these studies has a similar design to CABA-201, sharing the
Slide 10: Cabaletta's CD19 binder with similar activity to FMC63
Cabaletta’s CD19 binder with similar in vitro & in vivo activity to FMC631,2 (binder used in academic studies3,4) CABA-201: CD19-targeting CAR T therapy for autoimmune diseases SLE – Systemic lupus erythematosus; IIT – Investigator-initiated trial; Flu/Cy – Fludarabine/Cyclophosphamide; CRS – Cytoki
Slide 11: Myositis: Strong scientific rationale and significant disease burden
~66K U.S. patients with IIM subtypes with B cell involvement; frequently severe, with limited treatment options Myositis: Strong scientific rationale & significant disease burden Lundberg, Ingrid E., et al. "Idiopathic inflammatory myopathies." Nature Reviews Disease Primers 7.1 (2021): 86. Kronzer,
Slide 12: CABA-201 to be evaluated in patients with active myositis
CABA-201 to be evaluated in patients with active myositis, including DM, ASyS & IMNM Phase 1/2 study design for CABA-201 in patients with myositis DM – Dermatomyositis; ASyS – Anti-synthetase syndrome; IMNM – Immune-mediated necrotizing myopathy Subjects will be treated with a standard preconditioni
Slide 13: SLE and Lupus Nephritis: High unmet clinical need
~320,000 SLE patients in the U.S., ~40% with LN, who face increased risk of kidney failure & death SLE & Lupus Nephritis: High unmet clinical need Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH; National
Slide 14: CABA-201 to be evaluated in patients with active SLE
CABA-201 to be evaluated in patients with active SLE with or without renal involvement Phase 1/2 study design for CABA-201 in patients with SLE SLE – Systemic lupus erythematosus; EULAR – European League Against Rheumatism; ACR – American College of Rheumatology Subjects will be treated with a stand
Slide 15: Generalized Myasthenia Gravis: Expands development into neurology
Expands development of CABA-201 beyond rheumatology and into neurology Generalized Myasthenia Gravis (gMG): Antibody-mediated disease Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. Wendell LC, Levine JM. Myasthenic crisis. Neur
Slide 16: CABA-201 to be evaluated in generalized myasthenia gravis
CABA-201 to be evaluated in patients with generalized myasthenia gravis Phase 1/2 study design for CABA-201 in patients with gMG gMG – Generalized myasthenia gravis; AChR – Acetylcholine receptor; MGFA – Myasthenia Gravis Foundation of America Subjects will be treated with a standard preconditioning
Slide 17: Systemic Sclerosis: Profound unmet need and limited options
~88K SSc patients in the U.S., with intractable progression leading to chronic morbidity & high mortality1,2 Systemic Sclerosis (SSc): Profound unmet need & limited options Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated intersti
Slide 18: CABA-201 to be evaluated in systemic sclerosis
CABA-201 to be evaluated in patients with systemic sclerosis with severe skin or organ involvement Phase 1/2 study design for CABA-201 in patients with SSc SSc – Systemic sclerosis; EULAR – European League Against Rheumatism; ACR – American College of Rheumatology Subjects will be treated with a sta
Slide 19: Differentiated development path accelerating CABA-201
Our product candidate & uniquely experienced people inform our differentiated development path Accelerating development of CABA-201 for autoimmune diseases SLE – Systemic lupus erythematosus Peng, Binghao J, et al. “Preclinical specificity and activity of CABA-201, a fully human 4-1BB containing CD1
Slide 20: Chimeric AutoAntibody Receptor T Cells DSG3-CAART & MuSK-CAART
Chimeric AutoAntibody Receptor T Cells DSG3-CAART & MuSK-CAART
Slide 21: Enrolling in Flu/Cy/IVIg cohort in DesCAARTes study
Enrolling in Flu / Cy / IVIg cohort to evaluate ability to improve engraftment & clinical activity Ongoing DesCAARTes™ study in patients with mucosal PV Joly, Pascal, et al. "First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a
Slide 22: MusCAARTes study of MuSK-CAART
Additional opportunity to evaluate CAART platform in disease with differentiated biology Ongoing MusCAARTes™ study in patients MuSK+ MG MusCAARTes™ study of MuSK-CAART Ongoing open-label study to determine the maximum tolerated dose & to evaluate safety of MuSK-CAART Part Cohort Subjects A – Monothe
Slide 23: Corporate Summary
Corporate Summary Cabaletta Bio”
Slide 24: Three-stage manufacturing approach
Three-stage approach allows for efficient allocation of capital while leveraging experienced partners Manufacturing strategy Stage 3: Commercialization & Scale-Up Data-gated, staged investment Stage 1: Penn Stage 2: CDMOs & CABA Process Cell processing capacity secured through Penn partnership SOPs
Slide 25: Cabaletta Bio leadership
BOARD OF DIRECTORS Cabaletta Bio leadership LEADERSHIP TEAM Anup Marda Chief Financial Officer Arun Das, M.D. Chief Business Officer David J. Chang, M.D., M.P.H., FACR Chief Medical Officer Martha O’Connor Chief HR Officer Michael Gerard General Counsel Steven Nichtberger, M.D. President, CEO & Chai
Slide 26: Leveraging years of experience in cellular therapy for autoimmunity
Leveraging years of experience with cellular therapy in autoimmunity to initiate CABA-201 clinical trials Cabaletta®: Pursuing cures for a broad range of autoimmune diseases CARTA – Chimeric Antigen Receptor T cells for Autoimmunity; CAART – Chimeric AutoAntibody Receptor T cells; IND – Investigatio
Slide 27: Corporate Presentation NOVEMBER 2023
Corporate Presentation NOVEMBER 2023
Cabaletta Bio — Investor Presentation (November 2023) on 6ix